These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 12458324)

  • 1. Therapeutic vaccines against HPV16-associated tumors. Minireview.
    Bubeník J
    Neoplasma; 2002; 49(5):285-9. PubMed ID: 12458324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Animal models for development of therapeutic HPV16 vaccines (review).
    Bubeník J
    Int J Oncol; 2002 Jan; 20(1):207-12. PubMed ID: 11743666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preventative and therapeutic vaccines for cervical cancer.
    Roden R; Wu TC
    Expert Rev Vaccines; 2003 Aug; 2(4):495-516. PubMed ID: 14711335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
    Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
    Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic uterine-cervix cancer vaccines in humans.
    Gariglio P; Benitez-Bribiesca L; Berumen J; Alcocer JM; Tamez R; Madrid V
    Arch Med Res; 1998; 29(4):279-84. PubMed ID: 9887543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction and characterization of recombinant fowlpox viruses expressing human papilloma virus E6 and E7 oncoproteins.
    Pozzi E; Basavecchia V; Zanotto C; Pacchioni S; Morghen Cde G; Radaelli A
    J Virol Methods; 2009 Jun; 158(1-2):184-9. PubMed ID: 19428588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells.
    Sima N; Wang S; Wang W; Kong D; Xu Q; Tian X; Luo A; Zhou J; Xu G; Meng L; Lu Y; Ma D
    Gynecol Oncol; 2007 Aug; 106(2):299-304. PubMed ID: 17586029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccines against human papillomavirus and cervical cancer: promises and challenges.
    Mahdavi A; Monk BJ
    Oncologist; 2005 Aug; 10(7):528-38. PubMed ID: 16079320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RNA interference against HPV16 E7 oncogene leads to viral E6 and E7 suppression in cervical cancer cells and apoptosis via upregulation of Rb and p53.
    Sima N; Wang W; Kong D; Deng D; Xu Q; Zhou J; Xu G; Meng L; Lu Y; Wang S; Ma D
    Apoptosis; 2008 Feb; 13(2):273-81. PubMed ID: 18060502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins.
    Yugawa T; Kiyono T
    Rev Med Virol; 2009 Mar; 19(2):97-113. PubMed ID: 19156753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
    Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
    Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange.
    Subbaramaiah K; Dannenberg AJ
    Cancer Res; 2007 Apr; 67(8):3976-85. PubMed ID: 17440114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein intrinsic disorder and human papillomaviruses: increased amount of disorder in E6 and E7 oncoproteins from high risk HPVs.
    Uversky VN; Roman A; Oldfield CJ; Dunker AK
    J Proteome Res; 2006 Aug; 5(8):1829-42. PubMed ID: 16889404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin.
    Putral LN; Bywater MJ; Gu W; Saunders NA; Gabrielli BG; Leggatt GR; McMillan NA
    Mol Pharmacol; 2005 Nov; 68(5):1311-9. PubMed ID: 16120770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Notch1 can contribute to viral-induced transformation of primary human keratinocytes.
    Lathion S; Schaper J; Beard P; Raj K
    Cancer Res; 2003 Dec; 63(24):8687-94. PubMed ID: 14695182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A DNA vaccine encoding a codon-optimized human papillomavirus type 16 E6 gene enhances CTL response and anti-tumor activity.
    Lin CT; Tsai YC; He L; Calizo R; Chou HH; Chang TC; Soong YK; Hung CF; Lai CH
    J Biomed Sci; 2006 Jul; 13(4):481-8. PubMed ID: 16649071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer.
    Yamato K; Yamada T; Kizaki M; Ui-Tei K; Natori Y; Fujino M; Nishihara T; Ikeda Y; Nasu Y; Saigo K; Yoshinouchi M
    Cancer Gene Ther; 2008 Mar; 15(3):140-53. PubMed ID: 18157144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HPV16-specific cytotoxic T lymphocyte responses are detected in all HPV16-positive cervical cancer patients.
    Valdespino V; Gorodezky C; Ortiz V; Kaufmann AM; Roman-Basaure E; Vazquez A; Berumen J
    Gynecol Oncol; 2005 Jan; 96(1):92-102. PubMed ID: 15589586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transformation assays for HPV oncoproteins.
    Massimi P; Banks L
    Methods Mol Med; 2005; 119():381-95. PubMed ID: 16350412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.